Q-omics provides the consensus-scored DNM1P47 profile across patient tissues and cancer cell-line models. DNM1P47 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, DNM1P47 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, DNM1P47 RNA expression shows 18,863 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where DNM1P47 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNM1P47 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNM1P47 survival associations across molecular data types. DNM1P47 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNM1P47 RNA expression–survival associations across cancer types. High DNM1P47 expression shows unfavorable associations in LGG, ACC, MESO and UVM, but favorable associations in HNSC and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for DNM1P47 RNA expression.
This table summarizes DNM1P47 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DNM1P47. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNM1P47 shows lower tumor expression in BLCA, THCA, COAD, UCEC and BRCA and higher tumor expression in KIRC. The KIRC box plot shows higher DNM1P47 RNA expression in tumor versus normal tissue (log2 FC = +0.174, t-test p < 0.001).
This table shows molecular features associated with DNM1P47 in patient tissues and cancer cell lines. In patient samples, DNM1P47 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
